No Handa-cap as generic Seroquel licensee hits Par with US rights deal
This article was originally published in Scrip
Executive Summary
After establishing itself as the first manufacturer with rights to market a generic version of AstraZeneca's Seroquel XR (quetiapine fumarate extended-release tablets) in the US, Handa Pharmaceuticals has entered into an acquisition and license agreement with Par Pharmaceutical that gives Par exclusive rights to Handa's abbreviated new drug application (ANDA) for the antipsychotic drug.